Scholar Rock: CRL Obtained, But Resubmission Of Apitegromab Is Possible (NASDAQ:SRRK)

Group 1 - The article discusses Scholar Rock Holding Corporation (NASDAQ: SRRK) and its potential beyond its current focus on Spinal Muscular Atrophy (SMA) treatments, particularly highlighting upcoming data related to obesity treatment expected in Q2 2025 [2] - The author operates the Biotech Analysis Central service, which provides in-depth analysis of various pharmaceutical companies and includes a model portfolio of small and mid-cap stocks [2] - The service offers a subscription model with a promotional two-week free trial and a discounted annual plan [1] Group 2 - The article does not provide specific financial data or performance metrics related to Scholar Rock or the broader biotech industry [4]